G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-213-9835
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees44
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.08. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
7 analysts have issued 1 year price targets for G1 Therapeutics' stock. Their predictions range from $63.00 to $80.00. On average, they anticipate G1 Therapeutics' stock price to reach $72.60 in the next year. This suggests a possible upside of 260.7% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
What are Wall Street analysts saying about G1 Therapeutics stock?
Here are some recent quotes from research analysts about G1 Therapeutics stock:
- 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (8/8/2018)
- 2. BTIG Research analysts commented, "On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC." (3/7/2018)
Has G1 Therapeutics been receiving favorable news coverage?
Media headlines about GTHX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. G1 Therapeutics earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Endo International (ENDP), Reata Pharmaceuticals (RETA), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Mirati Therapeutics (MRTX), Opko Health (OPK) and Ironwood Pharmaceuticals (IRWD).
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Mr. Barclay A. Phillips, CFO, Sr. VP of Corp. Devel. & Sec. (Age 55)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 58)
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 54)
- Mr. Alexander D. Smith M.S., VP of Technical Operations
- Dr. Jay C. Strum, Chief Scientific Officer (Age 54)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Meeder Asset Management Inc. (0.01%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.
Which institutional investors are buying G1 Therapeutics stock?
GTHX stock was acquired by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Cynthia Schwalm, Fredric N Eshelman, James S Hanson, John Demaree and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $20.13.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $740.35 million. The company earns $-60,120,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. G1 Therapeutics employs 44 workers across the globe.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
